Nanosized and Enhancement of Solubility Fisetin
Fisetin (3,3,4,7-tetrahydroxyflavone) is a natural antioxidant that has shown to posses anticancer, antioxidant and anti-inflammatory properties. However, the poor solubility leads to poor bioavailability and limits its development.The aim of the research is to investigate the effect of fisetin nanosuspension using a nanoprecipitation technique and additional stabilizers polysorbat 80, SLS, PVA and Eudragit on particle size average, polydispersity index and zeta potential.The suspensions of microcrystalline FIS were prepared by a nanoprecipitation technique with different proportion of stabilizers fixed. The nanosuspension produced was then characterized using Photon Correlation Spectroscopy (PCS) in term of particle size distribution, polydispersity index, zeta potential and morphology nanosuspensiom (TEM). Result showed fisetin nanosuspension were successfully prepared by anti-solvent precipitation with additional stabilizer SLS and polysorbat 80. The nanosuspension containing polysorbat 80 showed smaller average particle size of 225.7 nm ± 1.31, a polydispersity index of 0.272 ±0.02 and zeta potential -39.3 ± 0.26 was obtained. Conclusion, FIS nanosuspension successfully prepared by nanoprecipitation tecnique with the polysorbate 80 as stabilizer and ethanol as solvent were spherical in shape..
2. Gacche RN. Shegokar. HD. Gond DS. Yang Z. Jadhav AD. Evaluation of selected flavonoids as antiangiogenic, anticancer, and radical scavenging agents: an experimental and in silico analysis. Cell Biochem Biophys.2011; 61:651–663.
3. Sindhi V. Gupta V. Sharma K. Bhatnagar S. Kumari R. Dhaka N. Potential applications of antioxidants- a review. Journal of Pharmacy Research.2013; 7: 828-835.
4. Leonarduzzi G. Testa G. Sottero B. Gamba P and Poli G. Design and development of nano vehicle-based delivery systems for preventive or therapeutic supplementation with flavonoids. Current Medicinal Chemistry. 2010; 17: 74-95.
5. OdehF. Al-Jaber H and KhaterD. Application of nanotechnology in drug delivery. New York: In Tech; 2014. p. 344-368.
6. ProcházkováD. BoušováI.Wilhelmová N. Antioxidant and prooxidant properties of flavonoids. Fitoterapia. 2011; 82: 513–523
7. Hu-JunX.Wang-ShuM.Fu-RongL.Jie-HuiX. Lei. Qun-FangL.Wen-JunF. Radical scavenging activity of fisetin, Acta Phys. -Chim. Sin.2013; 29 (7): 1421-1432.
8. HongC.DangY.LinG.YaoY.LiG.Ji G.ShenH.XieY. Effects of stabilizingagents on the development of myricetinnano suspension and its characterization: an in vitro and in vivo evaluation, International Journal of Pharmaceutics.2014; 477: 251–260.
9. Guzzo MR.Semi M.Donate PM. Nikolaou S.Antonio Eduardo H. Machado AEH.Okano LTA. Study of the complexation of fisetin with cyclodextrins. JournalPhysChem.2006;110 (36): 10545-1055.
10. Sowa M. Slepokura K. Matczak -Jon E. Improving solubility of fisetin by cocrystallization. Crys Eng Com. 2014; 16: 10592-10601.
11. Seguin J. Brulle L. Boyer R. Lu YM. Ramos Romano M. Touil YS. Liposomal encapsulation of the natural flavonoid fisetin
improves bioavailability and antitumor efficacy. International journal of pharmaceutics. 2013;444(1-2):146-54.
12. Wang L. Zhang DZ. Wang YX. Bioflavonoid fisetin loaded alpha-tocopherol-poly(lactic acid)-based polymeric micelles for enhanced anticancer efficacy in breast cancers. Pharmaceutical Research. 2017;34(2):453-61.
13. Bothiraja C. YojanaBDPawar AP. Shaikh KS and Thorat UH. Fisetin-loadednanocochleates: formulation and Characterization, in vitro anticancer testing, bioavailability and biodistribution study. Expert Opin. Drug Deliv. 2014; 11(1) : 17-29.
14. Al-Kassas R. Bansal M. Shaw J.Nanosizing techniques for improving bioavailability of drugs. Journal Control Release. 2017; 260 : 202 – 2012.
15. JunghannsAH and MüllerRH. Nanocrystal technology, drug delivery and clinical applications. International Journal of Nanomedicines. 2008; 3 (3): 295-309.
16. KeckCM. and MullerRH. Drug nanocrystal of poorly soluble drugs produced by high-pressure homogenization. Eur J Pharm Biopharm. 2008; 62 (1) 3-16.
17. Sinha B. Muller RH. Moschwitzer JP. Bottom-up approaches for preparing drug nanocrystals: formulations and factors affecting particle size. Int J Pharm. 2013;453(1):126-141.
18. JunyaprasertVB. and MorakulB. Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs. Asian Journal of Pharmaceutical Science. 2015; 10: 10-23.
19. De Waard H. Frijlink HW. Hinrichs WLJ. Bottom-up preparation techniques for nanocrystals of lipophilic drugs. Pharmaceutical Research. 2011; 28(5):1220-1223.
20. Möschwitzer JP. Drug nanocrystals in the commercial pharmaceutical development process. International Journal of Pharmaceutics. 2013;453(1):142-156.
21. Dzakwan M. Ganet E P. Mauludin R Wikarsa S. Formulation and characterization of fisetin nanosuspension. IOP Material Science. 2017; 259 (012016): 1-5.
22. Patravale V B. Date A A. Kulkarni R M. Nanosuspensions : a promising drug delivery strategy. J Pharm Pharmacol. 2004; 56:827-840.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).